Evidence mapPaperPMID 39030187Full record

SynthesisScientific reports2024

Chronic liver disease is an important risk factor for worse outcomes in acute pancreatitis: a systematic review and meta-analysis.

Jakub Hoferica, Ruben Zsolt Borbély, Ali Nedjati Aghdam, Eszter Ágnes Szalai, Ádám Zolcsák, Dániel Sándor Veres, Krisztina Hagymási, Bálint Erőss, Péter Hegyi, Peter Bánovčin and 1 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jakub HofericaCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Ruben Zsolt BorbélyCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Ali Nedjati AghdamCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Eszter Ágnes SzalaiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Ádám ZolcsákCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Dániel Sándor VeresCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Krisztina HagymásiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Bálint ErőssCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Péter HegyiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Peter Bánovčin *Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Péter Jenő Hegyi *Centre for Translational Medicine, Semmelweis University, Budapest, Hungary. hegyi.peter1@semmelweis-univ.hu.ORCID 0000-0002-6443-0259

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic liver diseases (CLD) affect 1.5 billion patients worldwide, with dramatically increasing incidence in recent decades. It has been hypothesized that the chronic hyperinflammation associated with CLD may increase the risk of a more severe course of acute pancreatitis (AP). This study aims to investigate the underlying impact of CLD on the outcomes of AP. A systematic search was conducted in Embase, Medline, and Central databases until October 2022. Studies investigating patients with acute pancreatitis and CLD, were included in the meta-analysis. A total of 14,963 articles were screened, of which 36 were eligible to be included. CLD was a risk factor for increased mortality with an odds ratio (OR) of 2.53 (CI 1.30 to 4.93, p = 0.01). Furthermore, renal, cardiac, and respiratory failures were more common in the CLD group, with ORs of 1.92 (CI 1.3 to 2.83, p = 0.01), 2.11 (CI 0.93 to 4.77, p = 0.062) and 1.99 (CI 1.08 to 3.65, p = 0.033), respectively. Moreover, the likelihood of developing Systemic Inflammatory Response Syndrome (SIRS) was significantly higher, with an OR of 1.95 (CI 1.03 to 3.68, p = 0.042). CLD is an important risk factor for worse outcomes in AP pancreatitis, leading to higher mortality and increased rates of local and systemic complications.

Indexed as

PancreatitisAcute DiseaseChronic DiseaseHumansLiver DiseasesOdds RatioRisk FactorsSystemic Inflammatory Response SyndromeAcute pancreatitisCirrhosisMetabolic-associated fatty liver diseaseNonalcoholic fatty liver diseaseSteatotic liver disease

Identifiers

PMID39030187
PMCPMC11271551

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.